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2012.09.0Abstract Aims: To evaluate the dosimetric proﬁle among three-dimensional conformal radiother-
apy (3D-CRT) and stereotactic radiotherapy (SRT) for the treatment of intracranial tumors.
Materials and methods: Seventeen patients with intra cranial tumors of benign nature or low malig-
nant potential were enrolled and planned for SRT as well as 3D-CRT.
Dosimetric comparison between these two plans was done considering the following parameters:
Target coverage, conformity index, and heterogeneity index.
Results: The dosimetric parameters of the 3D-CRT plans were a little inferior compared with those
for the SRT plans. The difference between mean target coverage, mean conformity index and mean
heterogeneity index for 3D-CRT and SRT plans was highly signiﬁcant at P< 0.001 (t = 7.74),
P< 0.001 (t = 5.52), and P< 0.01 (t = 3.15) respectively.
Conclusion: SRT is a very efﬁcient treatment option for intracranial tumors, in view of better target
coverage and conformality compared with 3D-CRT.
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01Introduction
External-beam radiation therapy (EBRT) is a component of
treatment for most primary intracerebral malignancies after
a maximal safe surgical resection. In addition to dose consid-
erations, the volume of brain irradiated to high dose must be
minimized.
The appropriate volume to encompass within the radiation
treatment portal varies with the speciﬁc histopathologic tumor
type. Benign tumors that typically do not inﬁltrate beyond theand hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
170 M. Gupta et al.lesional borders are seen by MRI. Certain tumors, such as be-
nign meningiomas, pituitary adenomas, craniopharyngiomas,
and acoustic neuromas, may be treated with narrow margins
of surrounding normal tissues. In contrast, most common
brain tumors, such as low-grade and malignant astrocytomas,
are inﬁltrative into surrounding normal brain tissues many
centimeters. Thus, a substantial amount of ‘‘normal’’ brain is
included in the full-dose volume. Newer technologies have
been developed to minimize the acute and long-term toxicities
of RT when this modality is indicated. Stereotactic radiation
therapy (SRT) uses highly focal, precise, fractionated radiation
therapy. This form of treatment is made possible with head
ﬁxation devices and modiﬁcations to standard linear accelera-
tors. SRT was developed using principles from stereotactic
radiosurgery, which uses a single large fraction of radiation
with an invasive head frame for immobilization. SRT com-
bines the advantages of focused precision RT with biologic
advantages of fractionation [1–4].
Stereotactic radiotherapy for intracranial tumors is of valu-
able importance over conventional radiotherapy in patients
who have a relatively high probability of long term survival,
that is patients with low-grade histology, localized tumor,
young age and benign histopathology. The long term sequelae
of irradiation of the brain in young children include neurocog-
nitive, endocrinologic, carcinogenic and vascular events. These
vary in severity, depending considerably on the age of the
child, the radiation dose, and the size of the radiation ﬁeld.
The goal of SRT is to minimize the amount of normal tissues
irradiated without compromising tumor control. The accuracy
and precision of SRT allows for smaller margin of normal tis-
sues to receive the prescription dose [4].
Given the potential advantages of the precise limited – ﬁeld
RT for intracranial tumors, we initiated a prospective study to
evaluate the dosimetric proﬁle among three-dimensional con-
formal radiotherapy (3D-CRT) and SRT for treatment of
intracranial tumors.
Materials and methods
From March-05 to June-07, biopsy proved 17 patients (except
patients with typical clinical and MRI ﬁndings suggestive of a
brain stem glioma or optic nerve meningioma) with localized
intracranial tumor of low-grade histopathology and malignant
potential were selected for the study. Detailed history and
thorough physical examination, including neurologic examina-
tion, and radiologic or any other investigation was done at the
time of registration.
Fractionated SRT was performed using a Clinac-DMX
2300-CD linear accelerator (Varian, Palo Alto, CA) and aTable 1 Patients’ characteristics.
Characteristics Median
1 Age 27 year
2 Gender
Male –
Female –
3 PTV 22.22 CC
4 KPS 80% (mode)m3-micromultileaf collimator (Brain LAB) ﬁxed on the gantry
of the linear accelerator, each leaf width 3-mm.
For treatment planning and delivery, patients were immobi-
lized in a relocatable stereotactic head frame (Brain LAB,
Heimsteten, Germany) with associated bite-block, occipital
impression, and facial aquaplast assuring an overall position-
ing accuracy of 1–2 mm. The planning CT scan with contrast,
with a Brain LAB CT localizer was attached to their head
frame using a 3-mm slice thickness. A contrast-enhanced
MRI was performed in the treatment position. CT and MRI
images and conﬁguration data were transmitted to a Brain
Scan apparatus for SRT planning. For treatment planning,
the position of the nine localizer rods on the CT slices were
used to map each voxel of the CT scan into the coordinate
space. The CT scan was fused to an axial MRI series using Ob-
ject pair matching for better deﬁnition of the target volume.
The T1-weighted post-contrast and T2-weighted images were
used to ensure adequate identiﬁcation of the tumor. After im-
age fusion, the target volume and organs at risk (OAR) were
delineated in each slice using the three dimensional treatment
planning Brain Scan software (version 5.3, Brain LAB AG).
The gross target volume (GTV) was deﬁned as the area with
contrast enhancement on T1-weighted MRI and the planning
target volume (PTV) included a 2–3 mm safety margin to allow
possible patient misalignment. Dose–volume histograms were
constructed. The prescription dose was chosen after evaluation
of the DVH, taking into account the location of the intracra-
nial tumor.
At the time of treatment, a Brain LAB laser localizer was
attached to the patient’s head frame and used to align the pa-
tient to the planned isocenter. A single isocenter was used in all
cases, with ﬁve to seven ﬁelds.
3D-CRT plan was created for each patient undergoing ste-
reotactic irradiation treatment, in ECLIPSE three dimensional
treatment planning system, using multileaf collimator (each
leaf width 1-cm), and CT scan and MRI images (used for
SRT planning).
For a fair comparison, the PTV margin was deﬁned as 3-
mm, and the speciﬁc prescription dose was set at 95% for all
the plans.
The target coverage, conformity index (CI), and heteroge-
neity index (HI) were used to compare the different plans in
this study. The target coverage was deﬁned as the percentage
of the PTV at the prescription dose. Conformity index (CI),
represents an attempt to measure objectively how well the dis-
tribution of radiation follows the shape of target. It was ex-
pressed as, CI = Vn/Vt (where Vn and Vt are the volume of
the normal tissues and target receiving the prescription dose,
respectively).Range No. of patients
7–75 year 17
– 12
– 5
7.90–145.2CC 17
60–90% 17
Table 2 Dosimetric comparison between 3D-CRT and SRT.
S. No. Parameter 3D-CRT SRT t-Value P-value
1 Target coverage
Mean 83.46% 95.74% 7.74 <0.001
SD 4.86 4.38
2 Conformity Index
Mean 1.46 1.07 5.52 <0.001
SD 0.290 0.028
3 Heterogeneity Index
Mean 1.103 1.105 3.15 <0.01
SD 0.0242 0.0343
Figure 1 Target coverage at prescription dose for 3D-CRT and
SRT plans.
Figure 2 Conformity index for 3D-CRT and SRT plans.
Figure 3 Heterogeneity index for 3D-CRT and SRT plans.
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(where D5% and D95% correspond to the dose delivered to
5% and 95% of the PTV, respectively).
Statistical analysis was done using SPSS, version 8.0.0, sta-
tistical software package. For quantitative data, ‘t’ test was ap-
plied to calculate the difference between two means.
Results
Patient characteristics are shown in Table 1.
Tumours were: acoustic schwannoma; meningioma involv-
ing right cavernous sinus, sellar and suprasellar region; astro-
cytic tumor involving optic chiasma; pineal gland tumor;arterio-venous malformation involving right parietal lobe
and left temporo-parietal area and other histologic types,
including pituitary adenoma, oligodendroglioma involving left
fronto-parietal region, chordoma involving right petrous apex,
craniopharyngioma, hemangioma involving pons (imaging
based diagnosis) (see Table 2).
Mean target coverage for 3D-CRT plan is 83.46% and for
SRT 95.74%. This difference in the mean was highly signiﬁ-
cant at P< 0.001 (t= 7.74). Mean of conformity index for
3D-CRT is 1.46 and for SRT is 1.07. This difference in the
mean was highly signiﬁcant at P< 0.001 (t= 5.52). Mean
of heterogeneity index for 3D-CRT plan is 1.103 and for
SRT plan 1.105. This difference in the mean was highly signif-
icant at P< 0.01 (t= 3.15) (see Figs. 1–3).
Discussion
Fractionated stereotactic radiotherapy (FSRT) is a potent,
noninvasive method of precise high-dose RT for localized be-
nign and malignant intracranial tumors [5]. Using a relocatable
stereotactic head frame for accurate immobilization and local-
ization, image fusion for accurate target delineation, and treat-
ment planning with multiple, static, conformal noncoplanar
beams, treatment plans with SRT are of high precision and
conformality [6]. Radical radiotherapy using innovative tech-
niques is undoubtedly effective for the treatment of inoperable
or recurrent intracranial tumors.
The natural evolution of these radiotherapy planning tech-
niques is to now consider intensity modulated stereotactic
172 M. Gupta et al.radiotherapy utilizing the localization/immobilization beneﬁts
of the stereotactic frame and the potential conformation ben-
eﬁt of IMRT, for example with dynamic micromultileaf colli-
mation [7]. In a replanning study of 10 patients with skull
base meningiomas, Baumert et al. [7] described improved
PTV coverage and a decrease in the dose to organs at risk with
intensity modulated stereotactic radiotherapy. Whether this
has a therapeutic gain for patients is yet to be demonstrated.
Ding et al. [8] investigated the dosimetric differences among
three-dimensional conformal radiotherapy (3D-CRT), dy-
namic conformal arc therapy (DCAT), and intensity-modu-
lated radiotherapy (IMRT) for brain tumor treatment. The
IMRT plans had a greater CI, better target coverage at the
prescription dose, and a better heterogeneity index. For large
tumors (PTV> 100 cm3), the IMRT plan had good target
coverage at the prescription dose, and heterogeneity index
and approximate CI values as those in the 3D-CRT and
DCAT plans. The results of their study have shown that
DCAT is suitable for most cases in the treatment of brain tu-
mors. For a small target, 3D-CRT is useful, and IMRT is not
recommended. For larger tumors, IMRT is superior to 3D-
CRT and very competitive in sparing critical structures, espe-
cially for big tumors.
Grzadziel et al. [9] presented a comparison of the dose dis-
tribution of conformal three-dimensional radiotherapy plans
with IMRT plans for cranial lesions in stereotactic radiother-
apy. Results revealed that greatest homogeneity was reached
in the conformal plans and IMRT plans with high planning
target volume priority in the optimization process. This conse-
quently led to a better probability of tumor control. Better
protection of organs at risk and thereby lower normal tissue
complication probabilities were achieved in the IMRT plans
with increased weighting of the organs at risk. These results
show the efﬁciency, as well as some limitations of the IMRT
techniques.
Zwicker et al. [10] demonstrated that the use of an MLC
with a leaf width of 5 mm (MLC-5) has signiﬁcant advantages
over an MLC with a leaf width of 10 mm (MLC-10) with re-
spect to target coverage and protection of normal tissues in
step-and-shoot IMRT of head and neck cancer. The use of
MLC-5 led to a signiﬁcantly higher conformity index and an
improvement of the 90% coverage of PTV1 (planning target
volume) and PTV2 compared with MLC-10.
Wang et al. [11] compared the impacts of multileaf collima-
tor (MLC) widths (standard MLC width of 10 mm [SMLC]
and micro-MLC width of 4 mm [MMLC]) on intensity-
modulated radiotherapy (IMRT) planning for nasopharyngeal
carcinoma (NPC). Ten patients with NPC were recruited in this
study. The average conformity index (CI) and homogeneous
index (HI) for the planning gross target volume in IMRT plans
with MMLC were 0.790 ± 0.036 and 1.062 ± 0.011, respec-
tively. Data in plans with SMLC were 0.754 ± 0.038 and
1.070 ± 0.010, respectively. The differences were statistically
signiﬁcant (P< 0.05). Compared with CI and HI for planning
target volume in paired plans, data with MMLC obviously
were better than those with SMLC (CI: 0.858 ± 0.026 vs.
0.850 ± 0.021, P< 0.05; and HI: 1.185 ± 0.011 vs.
1.195 ± 0.011, P< 0.05). According to these two kinds of
Elekta MLC devices, IMRT plans with the MMLC have signif-
icant advantages in dose coverage for the targets, with more
efﬁciency in treatment for NPC.Fujimoto et al. [12] evaluated the dosimetric impact of
treatment planning for three-dimensional conformal radio-
therapy (3DCRT) and intensity-modulated radiotherapy
(IMRT) of prostate cancer using Varian/BrainLAB 120-leaf
high-deﬁnition multileaf collimator (HD120 MLC) with
2.5-mm leaf width and Varian 120-leaf millennium multileaf
collimator (M120 MLC) with 5 mm leaf width. The results
of this work demonstrated that the dose conformity of PTV
improved and the dose of bladder and rectum decreased for
3DCRT and IMRT of prostate cancer using HD120 MLC
compared to M120 MLC, because of the reduction of leaf
width, leaf transmission, and rounded leaf end transmission.
In our study, the dosimetric impact of treatment planning
for three-dimensional conformal radiotherapy (3DCRT) and
stereotactic radiotherapy (SRT) of intracranial tumors using
Varian/BrainLAB micromultileaf collimator with 3 mm leaf
width and Varian multileaf collimator with 10 mm leaf width,
demonstrated that the dosimetric parameters of the 3D-CRT
plans were a little inferior compared with those for the SRT
plans. The difference between mean target coverage, mean
conformity index and mean Heterogeneity index for 3D-
CRT and SRT plans was highly signiﬁcant at P< 0.001
(t= 7.74), P< 0.001 (t= 5.52), P< 0.01 (t= 3.15),
respectively.
Conclusion
In view of better target coverage, conformity index and heter-
ogeneity index, SRT for the treatment of benign intracranial
tumors is practical, safe and effective. SRT is a very efﬁcient
treatment option for asymptomatic and high-risk patients with
benign intracranial tumor (tumor volume >4 cc, distance to
adjacent critical structures less than 2 mm, and recurrences),
especially in cases of cavernous sinus – invading meningiomas
and those that compress the optical pathways.
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